109.35
0.88%
0.95
Schlusskurs vom Vortag:
$108.40
Offen:
$109.86
24-Stunden-Volumen:
1.10M
Relative Volume:
1.03
Marktkapitalisierung:
$219.52B
Einnahmen:
$49.94B
Nettoeinkommen (Verlust:
$17.60B
KGV:
29.40
EPS:
3.72
Netto-Cashflow:
$12.51B
1W Leistung:
-3.90%
1M Leistung:
-4.54%
6M Leistung:
+12.15%
1J Leistung:
+16.01%
Novartis Ag Adr Stock (NVS) Company Profile
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-09-05 | Herabstufung | Goldman | Buy → Neutral |
2024-09-03 | Herabstufung | Jefferies | Buy → Hold |
2024-07-19 | Herabstufung | Deutsche Bank | Buy → Hold |
2024-05-30 | Eingeleitet | Goldman | Buy |
2024-02-23 | Eingeleitet | BMO Capital Markets | Market Perform |
2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
2024-01-16 | Fortgesetzt | UBS | Buy |
2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
2023-09-25 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-04-26 | Hochstufung | Deutsche Bank | Hold → Buy |
2023-03-27 | Hochstufung | Deutsche Bank | Sell → Hold |
2023-01-26 | Herabstufung | Citigroup | Buy → Neutral |
2022-12-05 | Hochstufung | Stifel | Hold → Buy |
2022-09-15 | Herabstufung | Credit Suisse | Neutral → Underperform |
2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
2022-05-09 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2022-01-10 | Fortgesetzt | Citigroup | Buy |
2021-12-14 | Herabstufung | Redburn | Buy → Neutral |
2021-12-06 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
2021-12-03 | Herabstufung | Bryan Garnier | Buy → Neutral |
2021-09-20 | Herabstufung | Deutsche Bank | Hold → Sell |
2021-03-22 | Eingeleitet | Bernstein | Mkt Perform |
2021-03-10 | Herabstufung | Argus | Buy → Hold |
2021-02-01 | Herabstufung | Cowen | Outperform → Market Perform |
2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
2020-09-29 | Eingeleitet | Berenberg | Buy |
2020-09-10 | Hochstufung | UBS | Neutral → Buy |
2020-09-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-06-15 | Hochstufung | Citigroup | Neutral → Buy |
2020-03-10 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2020-02-25 | Herabstufung | Guggenheim | Buy → Neutral |
2019-04-25 | Hochstufung | Guggenheim | Neutral → Buy |
2019-04-25 | Hochstufung | Liberum | Hold → Buy |
2019-04-10 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2019-01-02 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-12-11 | Fortgesetzt | Jefferies | Buy |
2018-10-09 | Eingeleitet | Guggenheim | Neutral |
2018-09-10 | Hochstufung | BofA/Merrill | Underperform → Buy |
2018-05-29 | Herabstufung | HSBC Securities | Buy → Hold |
2018-05-25 | Hochstufung | Credit Suisse | Underperform → Neutral |
2018-01-25 | Bestätigt | Leerink Partners | Outperform |
2017-12-06 | Herabstufung | BofA/Merrill | Neutral → Underperform |
2017-07-26 | Hochstufung | Morgan Stanley | Underweight → Overweight |
2017-07-05 | Herabstufung | Credit Suisse | Neutral → Underperform |
2017-03-09 | Eingeleitet | Liberum | Buy |
Alle ansehen
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Our commitment to ethical and responsible use of Artificial Intelligence (AI) - Novartis
Novartis on Pace for Largest Percent Decrease Since March 2021 — Data Talk - Morningstar
Chemical Biology in Biomedical Research - Novartis
Radioligand therapy: delivering now, building for the future - Novartis
Novartis Financial Results – Q2 2024 - Novartis
Inclusivity - Novartis
Collaborations - Novartis
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial - GlobeNewswire Inc.
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance
5 Large Drug Stocks Likely To Outpace Q3 Earnings Estimates - Barchart
21 Best Healthcare Companies to Invest In - Morningstar
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move - sharewise
Saudi Arabia Generic Pharmaceutical Products Market Report 2024-2031, Featuring Profiles of Key Players - GlobeNewswire Inc.
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
Roche Wins FDA Nod For Breast Cancer Drug In First-Line Setting - Barchart
Denmark Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research
Norway Aspergillosis Treatment Market Size & Outlook, 2030 - Grand View Research
Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine
NVS: 3 European Stocks to Watch as the EU Economy Strengthens - StockNews.com
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-term Growth - Morningstar
Europe Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research
Australia Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research
Novartis Wins FDA Approval Of Kisqali For Early Breast Cancer - Barchart
Novartis' Kisqali Lowers Risk Of Breast Cancer Recurrence By 28% - Barchart
North America Immune Health Supplements Market Size & Outlook, 2030 - Grand View Research
Weekly Upgrades and Downgrades - InvestorPlace
Top investors say Novartis AG ADR (NVS) ticks everything they need - SETE News
Novartis lower as BofA downgrades on risks to valuation - MSN
Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - GlobeNewswire Inc.
Morgan Stanley cuts Novartis rating amid limited innovation - Baystreet.ca
Spain Congestive Heart Failure Drugs Market Size & Outlook, 2030 - Grand View Research
Market Insight: Novartis AG ADR (NVS)’s Notable Drop, Closing at 118.50 - The Dwinnex
Canada Cell And Gene Therapy CDMO Market Size & Outlook, 2030 - Grand View Research
The United States Erythropoietin Drugs Market Size & Outlook, 2030 - Grand View Research
China Biotechnology Market Size & Outlook, 2023-2030 - Grand View Research
Kuwait Gout Therapeutics Market Size & Outlook, 2023-2030 - Grand View Research
Finanzdaten der Novartis Ag Adr-Aktie (NVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):